495
Participants
Start Date
January 31, 2014
Primary Completion Date
March 31, 2019
Study Completion Date
November 30, 2019
BBI608
Fluorouracil
Oxaliplatin
Leucovorin
Irinotecan
Bevacizumab
Capecitabine
Regorafenib
Medical University of South Carolina, Charleston
Institute for Translational Oncology Research, Greenville Health System, Greenville
Emory University Winship Cancer Institute, Atlanta
Florida Cancer Specialists, Fort Myers
Tennessee Oncology - Nashville, Nashville
Tennessee Oncology - Chattanooga, Chattanooga
Oncology Hematology Care, Inc., Cincinnati
Indiana University Simon Cancer Center, Indianapolis
Indiana University Health Goshen Center for Cancer Care, Goshen
Parkview Research Center, Fort Wayne
Indiana University Health Ball Memorial Hospital, Muncie
Indiana University Health Arnett Hospital, Lafayette
Mayo Clinic, Rochester
Mayo Clinic Campus in Arizona, Phoenix
Ottawa Hospital Cancer Center, Ottawa
Sumitomo Pharma America, Inc.
INDUSTRY